INRLF (Valneva SE) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INRLF Valneva SE INRLF
52 GF Score
Price $2.43
GF Value $2.39
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Short-term investments?

Short-term investments only applies to insurance companies.

INRLF
52GF Score
Valneva SE INRLF
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be overvalued. The current stock price of $2.43 is trading 1.5% above its estimated GF Value™ of $2.39. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • Short-term investments:
  • GF Value™: $2.39 vs. price of $2.43 (1.5% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
52GF Score

Get the complete analysis for INRLF

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.43
Price
$2.39
GF Value